Clinical Trials Genetic Disorders Huntington's Disease Cardiovascular Health Phage Therapy Gene Editing Hearing Impairment Personalized Medicine CRISPR Technology Ophthalmology mRNA Technology Gene Manipulation MicroRNA Treatments Targeted Therapy Adeno-Associated Virus (AAV) mRNA Vaccines AFM-Téléthon Sickle Cell Disease Heart Failure Epigenetic Editing Duchenne Muscular Dystrophy OTOF Gene OTOF Gene Therapy AAV Vectors Neurological Diseases Acoustic Stimulation Liver Diseases Antisense Oligonucleotides Neuroscience RNA Interference (RNAi) Hearing Loss DNA Repair Congenital Deafness Hearing Disorders X-SCID Treatment HIV Gene Therapy Cancer Research Cytokine Research Safety Testing Cell Therapy Therapeutic Applications Pediatric Gene Therapy Neurodegenerative Diseases Neurological Disorders Genetic Modifications Genome Editing Techniques Infectious Diseases Gene Silencing MicroRNA Tumor Angiogenesis Clinical Evaluation Diabetic Kidney Disease Inherited Disorders Biotechnology Hearing Restoration Non-Viral Techniques Quality Control CRISPR Applications Blood Disorders RNA Interference Inherited Conditions Viral Vectors siRNA Therapy Sarepta Therapeutics MicroRNA Applications
The agreement deepens Lilly’s push into ophthalmic gene medicines following its October move to buy Adverum Biotechnologies.